Search

Date 2017 Author/Creator Lambert, T.

1. Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study. Issue 2 (16th August 2017)

Authors:
Liesner, R. J.; Abashidze, M.; Aleinikova, O.; Altisent, C.; Belletrutti, M. J.; Borel‐Derlon, A.; Carcao, M.; Chambost, H.; Chan, A. K. C.; Dubey, L.; Ducore, J.; Fouzia, N. A.; Gattens, M.; Gruel, Y.; Guillet, B.; Kavardakova, N.; El Khorassani, M.; Klukowska, A.; Lambert, T.; Lohade, S.
Journal:
Haemophilia
Issue:
Volume 24:Issue 2(2018)
Page Start:
211
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Issue 2 (15th February 2017)

Authors:
Iorio, A.; Barbara, A. M.; Makris, M.; Fischer, K.; Castaman, G.; Catarino, C.; Gilman, E.; Kavakli, K.; Lambert, T.; Lassila, R.; Lissitchkov, T.; Mauser‐Bunschoten, E.; Mingot‐Castellano, M. E.; Ozdemir, N.; Pabinger, I.; Parra, R.; Pasi, J.; Peerlinck, K.; Rauch, A.; Roussel‐Robert, V.
Journal:
Haemophilia
Issue:
Volume 23:Issue 2(2017)
Page Start:
255
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study. Issue 2 (13th December 2017)

Authors:
Négrier, C.; Ducloy‐Bouthors, A.‐S.; Piriou, V.; De Maistre, E.; Stieltjes, N.; Borel‐Derlon, A.; Colson, P.; Picard, J.; Lambert, T.; Claeyssens, S.; Boileau, S.; Bertrand, A.; André, M.‐H.; Fourrier, F.; Ozier, Y.; Sié, P.; Gruel, Y.; Tellier, Z.
Journal:
Vox sanguinis
Issue:
Volume 113:Issue 2(2017)
Page Start:
120
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search